ISMPP Highlights
ISMPP West 2019: A Pivotal Educational Meeting
ISMPP West 2019 proved to be a pivotal meeting for the Society’s educational presence on the US West Coast. This second-ever ISMPP West, held November 14-15, 2019, was highly regarded and was well-attended with 124 participants, topping last year’s ISMPP West…
GPP4: Development Is Underway
ISMPP is honored to have the opportunity to sponsor the next iteration of the Good Publication Practice (GPP) guidelines, an industry-leading document to guide the ethical development of medical publications. Development of the GPP4 guidelines is now well underway, with a Steering Committee established and working steadily on revisions to the guidance…
Open Pharma Releases Position Statement on Open Access
Open Pharma recently released its Position Statement on Open Access, which advocates that access to pharmaceutical company-funded research should not be restricted by journal paywalls. The Position Statement points out that approximately half of all biomedical research is funded by pharmaceutical companies. In the Position Statement, Open Pharma sets out its…
Message from Our Leadership - NEW!
Robert J. Matheis
ISMPP President and CEO
News and Trends
The Year in Review / The Year Ahead
“The only constant is change,” attributed to Heraclitus ca 500 BC, holds true for medical publication professionals in the 21st century. At times, it may feel like every week brings an announcement of a new regulation, guideline, protocol, or requirement, and we must always adapt, adjust, and move forward in kind. “The Year in Review/The Year Ahead”…
One Year Later: Have ICMJE Data Sharing Statement Requirements Impacted Medical Publishing?
In June 2017, ICMJE advised the research community that all clinical trial manuscripts submitted to ICMJE journals after July 1, 2018 would require a data sharing statement for the manuscript to be considered for publication… The MAP Working Group and the Global Trends and Transparency Committee undertook…
What I Would Like You to Know: A Real-World Evidence Expert’s Perspective
What are one or two things you want your medical publication colleagues to know from your experience of working on real-world evidence (RWE) publications? First, research models and applications for RWE are quite different from clinical trials. Even the terminology involved is different…
What Would You Do?
In our role as medical publication professionals, we may occasionally encounter situations in which it is not obvious how to ensure good publication practice. Have you ever wished you could consult the ISMPP membership for guidance when these situations arise? Here’s your opportunity!
What Would You Do? is a new section of The MAP that presents case scenarios as an educational tool for medical publication professionals. The section provides a case scenario to ponder, and readers are invited to participate in a poll by selecting one of the listed solutions. Readers can also submit their thoughts on the scenario anonymously. The poll results, plus educational insights, are posted in a later issue for readers to digest.
NEW POLL: The Authorship Order Dilemma
You are a company medical publication professional. The publication steering committee of a company-sponsored pivotal phase 3 clinical trial has selected investigators to serve as authors, but the committee and authors are having difficulty in deciding the order of authorship. During discussions, multiple authors believe that they have equal rights to the first author position based on their contributions…
ISMPP (pronounced IzMap) is the only nonprofit organization founded by medical publication professionals for medical publication professionals